The effect of combinated treatment of a metastatic HER2-positive stomach cancer
Trastuzumab in combination with standard chemotherapy has shown its effectiveness in treating HER2-positive metastatic gastric cancer. The median overall survival in its application is 16,8 months compared with 11,8 months when chemotherapy using alone. Authors demonstrate the case of the successful...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Habib O.N.
2014-12-01
|
| Series: | Современная онкология |
| Subjects: | |
| Online Access: | https://modernonco.orscience.ru/1815-1434/article/view/26960 |
| _version_ | 1818911557118066688 |
|---|---|
| author | R A Khvastunov A Yu Nenarokomov S E Tolstopiatov K G Babina |
| author_facet | R A Khvastunov A Yu Nenarokomov S E Tolstopiatov K G Babina |
| author_sort | R A Khvastunov |
| collection | DOAJ |
| description | Trastuzumab in combination with standard chemotherapy has shown its effectiveness in treating HER2-positive metastatic gastric cancer. The median overall survival in its application is 16,8 months compared with 11,8 months when chemotherapy using alone. Authors demonstrate the case of the successful using trastuzumab in the third line chemotherapy in patients with primary unresectable metastatic gastric cancer. As a result of the 12 courses of therapy almost complete tumor regression was achieved. It allowed to perform R0- gastrectomy. Currently, the patient continues trastuzumab treating in monoregime. |
| first_indexed | 2024-12-19T23:00:35Z |
| format | Article |
| id | doaj.art-0d27733eafb24e0895585d54f7da7d33 |
| institution | Directory Open Access Journal |
| issn | 1815-1434 1815-1442 |
| language | Russian |
| last_indexed | 2024-12-19T23:00:35Z |
| publishDate | 2014-12-01 |
| publisher | IP Habib O.N. |
| record_format | Article |
| series | Современная онкология |
| spelling | doaj.art-0d27733eafb24e0895585d54f7da7d332022-12-21T20:02:30ZrusIP Habib O.N.Современная онкология1815-14341815-14422014-12-01164212324180The effect of combinated treatment of a metastatic HER2-positive stomach cancerR A Khvastunov0A Yu Nenarokomov1S E Tolstopiatov2K G Babina3Volgograd State medical university (400131, pl. Pavshikh Bortsov 1a, Volgograd, Russia); Volgograd regional clinical oncologic dispensary №1Volgograd State medical university (400131, pl. Pavshikh Bortsov 1a, Volgograd, Russia)Volgograd State medical university (400131, pl. Pavshikh Bortsov 1a, Volgograd, Russia)Volgograd regional clinical oncologic dispensary №3, VolzhskyTrastuzumab in combination with standard chemotherapy has shown its effectiveness in treating HER2-positive metastatic gastric cancer. The median overall survival in its application is 16,8 months compared with 11,8 months when chemotherapy using alone. Authors demonstrate the case of the successful using trastuzumab in the third line chemotherapy in patients with primary unresectable metastatic gastric cancer. As a result of the 12 courses of therapy almost complete tumor regression was achieved. It allowed to perform R0- gastrectomy. Currently, the patient continues trastuzumab treating in monoregime.https://modernonco.orscience.ru/1815-1434/article/view/26960her2-povitive gastric cancertrastuzumabtarget therapy |
| spellingShingle | R A Khvastunov A Yu Nenarokomov S E Tolstopiatov K G Babina The effect of combinated treatment of a metastatic HER2-positive stomach cancer Современная онкология her2-povitive gastric cancer trastuzumab target therapy |
| title | The effect of combinated treatment of a metastatic HER2-positive stomach cancer |
| title_full | The effect of combinated treatment of a metastatic HER2-positive stomach cancer |
| title_fullStr | The effect of combinated treatment of a metastatic HER2-positive stomach cancer |
| title_full_unstemmed | The effect of combinated treatment of a metastatic HER2-positive stomach cancer |
| title_short | The effect of combinated treatment of a metastatic HER2-positive stomach cancer |
| title_sort | effect of combinated treatment of a metastatic her2 positive stomach cancer |
| topic | her2-povitive gastric cancer trastuzumab target therapy |
| url | https://modernonco.orscience.ru/1815-1434/article/view/26960 |
| work_keys_str_mv | AT rakhvastunov theeffectofcombinatedtreatmentofametastaticher2positivestomachcancer AT ayunenarokomov theeffectofcombinatedtreatmentofametastaticher2positivestomachcancer AT setolstopiatov theeffectofcombinatedtreatmentofametastaticher2positivestomachcancer AT kgbabina theeffectofcombinatedtreatmentofametastaticher2positivestomachcancer AT rakhvastunov effectofcombinatedtreatmentofametastaticher2positivestomachcancer AT ayunenarokomov effectofcombinatedtreatmentofametastaticher2positivestomachcancer AT setolstopiatov effectofcombinatedtreatmentofametastaticher2positivestomachcancer AT kgbabina effectofcombinatedtreatmentofametastaticher2positivestomachcancer |